ArticleJournal of nanobiotechnology2025
Genetically engineered Magnesium/Manganese nanoparticles for cancer radioimmunotherapy.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Biomaterial-driven remove-remodel-repair (3R) strategy for full-cycle gastric cancer management: bibliometric mapping, preclinical evidence, and a translational roadmap.Nanoscale advances · 2026Review
- Nano-Metal Hydrogen Therapy Targeting Immune Cells Drives Synergistic Anti-Tumor Effects.Molecules (Basel, Switzerland) · 2026Review
- Beyond apoptosis: nanomedicine enabled reprogramming of tumor cell death for next-generation radiosensitization.Journal of nanobiotechnology · 2026Review
- Mechanisms and Applications of Manganese-Based Materials in Tumor Immunotherapy.Molecules (Basel, Switzerland) · 2026Review
- Metal-based nanodrugs for cancer immunotherapy: smart nanosystems, immunomodulatory mechanisms, and translational perspectives.Frontiers in chemistry · 2026Review
- Metal Nanoparticles as Sensitizers in Energy-Based Therapies for Lung Cancer: From Mechanistic Insights to Clinical Translation.International journal of nanomedicine · 2026Review
- T lymphocyte membrane bionic nanomedicine synergizes with radiotherapy for enhancing MgTheranostics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Radiotherapy (RT) has great potential on activating antitumor immunity for combination therapy, yet this effect is limited by immunosuppressive tumor microenvironment (TME) and the potential toxicity in immune cells from high-dose radiation. Herein, we developed engineered nanoparticles (NPs) (CVs@MgMn) composed of genetically edited cellular vesicles (CVs), MnO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.